Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers

In vaccine design, antigens are often arrayed in a multivalent nanoparticle form, but in vivo mechanisms underlying the enhanced immunity elicited by such vaccines remain poorly understood. We compared the fates of two different heavily glycosylated HIV antigens, a gp120-derived mini-protein and a l...

Full description

Bibliographic Details
Main Authors: Tokatlian, Talar, Read, Benjamin J., Jones, Christopher A., Kulp, Daniel W., Menis, Sergey, Chang, Jason Y. H., Steichen, Jon M., Kumari, Sudha, Allen, Joel D., Dane, Eric L., Liguori, Alessia, Sangesland, Maya, Lingwood, Daniel, Crispin, Max, Schief, William R., Irvine, Darrell J
Other Authors: Harvard University--MIT Division of Health Sciences and Technology
Format: Article
Language:English
Published: American Association for the Advancement of Science (AAAS) 2020
Online Access:https://hdl.handle.net/1721.1/126252
Description
Summary:In vaccine design, antigens are often arrayed in a multivalent nanoparticle form, but in vivo mechanisms underlying the enhanced immunity elicited by such vaccines remain poorly understood. We compared the fates of two different heavily glycosylated HIV antigens, a gp120-derived mini-protein and a large, stabilized envelope trimer, in protein nanoparticle or “free” forms after primary immunization. Unlike monomeric antigens, nanoparticles were rapidly shuttled to the follicular dendritic cell (FDC) network and then concentrated in germinal centers in a complement-, mannose-binding lectin (MBL)–, and immunogen glycan–dependent manner. Loss of FDC localization in MBL-deficient mice or via immunogen deglycosylation significantly affected antibody responses. These findings identify an innate immune–mediated recognition pathway promoting antibody responses to particulate antigens, with broad implications for humoral immunity and vaccine design.